STATE-OF-THE ART VACCINE
Our Pipeline
We are developing a novel protein-only vaccine based on fusions of highly immunogenic and protective protein domains derived from selected surface proteins of Group B Streptococcus (GBS), specifically from the Alpha-like protein family (AlpN).
Key programs
*We have identified a number of novel AlpN GBS monoclonal antibodies with high killing ability that could have the potential to prevent or treat GBS infection. These are in early development and the business case is currently being explored.